MMMerel van der Meulen

Merel van der Meulen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merel van der Meulen has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RUNX1-ETO oncoprotein levels determine the balance between endothelial reprogramming and pre-leukemic growth in a human ES cell model of AML

    by Katerina Terolli, Floyd Hassenrueck, Alexander Maytum, Peter Keane, Lea Flippe, Sophie G. Kellaway, Merel van der Meulen, Olaf T. Heidenreich, Edouard G. Stanley, Elizabeth S. Ng, et al.

  • Top Cited Papers
    Open Access

    Single-cell multiomic atlas of healthy pediatric bone marrow reveals age-dependent differences in lineage differentiation driven by stromal signaling

    by Evelyn S. Hanemaaijer, Konradin F. Müskens, Ireen J. Kal, Li-Ting Chen, Brigit M. Te Pas, Patrycja Fryzik, Nina Epskamp, Merel van der Meulen, Aleksandra K. Balwierz, Akshaya K. Saikumar Jayalatha, et al.

    Childhood is a critical period for hematopoietic development and susceptibility to hematologic disease. Here we generated a multimodal single-cell atlas of healthy human bone marrow, capturing mRNA and surface protein expression in 90,710 cells, including over 20,000 hematopoietic stem and progenitor cells (HSPC) and mesenchymal stromal cells (MSC) from nine donors ranging from infancy to young adulthood (2–32 years). Young pediatric (YP) bone marrow (+ LyP cells with B cell-biased output were enriched before age 10, whereas CD127− LyP cells with combined lymphoid and myeloid features predominated thereafter. Stromal signaling showed corresponding age-dependent changes, with increased interleukin-7 production by bone marrow MSC in YP compared to AYA, indicating niche-mediated regulation of HSPC lineage potential during ontogeny. This single-cell atlas provides a comprehensive resource for understanding hematopoietic development and early-life origins of hematologic disease.


  • Open Access

    An Unexpected Case of Somatic Mosaicism of the Dutch p16‐ Leiden Founder Variant in the CDKN2A Gene

    by M van der Meulen, J T van Wezel, D Terlouw, J Morreau, E M P Steeghs, R van Doorn, M E van Leerdam, A M Onnekink, M C de Ruiter, N van der Stoep, et al.

    CDKN2A is the primary high‐risk predisposition gene for familial cutaneous melanoma. In the Netherlands, most carriers of pathogenic germline variants in CDKN2A harbor a unique, population‐specific founder variant, c.225_243del, commonly referred to as p16‐ Leiden . For decades, this distinctive 19 base‐pair deletion in CDKN2A had been identified exclusively as a germline variant. Here, we report an exceptional case of somatic mosaicism for the p16‐ Leiden variant in an Irish male with a concurrent diagnosis of Kartagener’s syndrome but no history of malignancy. The variant was first identified through targeted next‐generation sequencing (NGS) of a fundic gland polyp in the distal esophagus, showing a variant allele frequency (VAF) of 40%. Subsequent analysis also detected the variant in the patient’s buccal swab DNA (VAF 0.3%), while it was notably absent in multiple other tissue samples, including blood, urine, skin, and several additional samples from the proximal gastrointestinal tract. We explore several hypotheses that could explain these intriguing findings.

  • Open Access

    Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis

    by Anne-Sophie C A M Koning, Merel van der Meulen, Daphne Schaap, Djaina D Satoer, Christiaan H Vinkers, Elisabeth F C van Rossum, Wouter R van Furth, Alberto M Pereira, Onno C Meijer, Olaf M Dekkers

    Context: Synthetic glucocorticoids are widely used to treat patients with a broad range of diseases. While efficacious, glucocorticoids can be accompanied by neuropsychiatric adverse effects. Objective: This systematic review and meta-analysis assesses and quantifies the proportion of different neuropsychiatric adverse effects in patients using synthetic glucocorticoids. Methods: Six electronic databases were searched to identify potentially relevant studies. Randomized controlled trials, cohort studies, and cross-sectional studies assessing psychiatric side effects of glucocorticoids measured with validated questionnaires were eligible. Risk of bias was assessed with RoB 2, ROBINS-I, and AXIS appraisal tool. For proportions of neuropsychiatric outcomes, we pooled proportions, and when possible, differences in questionnaire scores between glucocorticoid users and nonusers were expressed as standardized mean differences (SMD). Data were pooled in a random-effects logistic regression model. Results: We included 49 studies with heterogeneity in study populations, type, dose, and duration of glucocorticoids. For glucocorticoid users, meta-analysis showed a proportion of 22% for depression (95% CI, 14%-33%), 11% for mania (2%-46%), 8% for anxiety (2%-25%), 16% for delirium (6%-36%), and 52% for behavioral changes (42%-61%). Questionnaire scores for depression (SMD of 0.80 [95% CI 0.35-1.26]), and mania (0.78 [0.14-1.42]) were higher than in controls, indicating more depressive and manic symptoms following glucocorticoid use. Conclusion: The heterogeneity of glucocorticoid use is reflected in the available studies. Despite this heterogeneity, the proportion of neuropsychiatric adverse effects in glucocorticoid users is high. The most substantial associations with glucocorticoid use were found for depression and mania. Upon starting glucocorticoid treatment, awareness of possible psychiatric side effects is essential. More structured studies on incidence and potential pathways of neuropsychiatric side effects of prescribed glucocorticoids are clearly needed.


  • Open Access

    Transcriptional glucocorticoid effects in the brain: Finding the relevant target genes

    by Onno C. Meijer, Jacobus C. Buurstede, Eva M. G. Viho, Jorge Miguel Amaya, Anne‐Sophie C. A. M. Koning, Merel van der Meulen, Lisa T. C. M. van Weert, Susana N. Paul, Jan Kroon, Lisa L. Koorneef

    Glucocorticoids are powerful modulators of brain function. They act via mineralocorticoid and glucocorticoid receptors (MR and GR). These are best understood as transcription factors. Although many glucocorticoid effects depend on the modulation of gene transcription, it is a major challenge to link gene expression to function given the large‐scale, apparently pleiotropic genomic responses. The extensive sets of MR and GR target genes are highly specific per cell type, and the brain contains many different (neuronal and non‐neuronal) cell types. Next to the set “trait” of cellular context, the “state” of other active signaling pathways will affect MR and GR transcriptional activity. Here, we discuss receptor specificity and contextual factors that determine the transcriptional outcome of MR/GR signaling, experimental possibilities offered by single‐cell transcriptomics approaches, and reflect on how to make sense of lists of target genes in relation to understanding the functional effects of steroid receptor activation.


  • Open Access

    Long‐term effects of glucocorticoid excess on the brain

    by Alies J. Dekkers, Jorge Miguel Amaya, Merel van der Meulen, Nienke R. Biermasz, Onno C. Meijer, Alberto M. Pereira

    The metabolic and cardiovascular clinical manifestations in patients with Cushing's syndrome (CS) are generally well known. However, recent studies have broadened the perspective of the effects of hypercortisolism, showing that both endogenous and exogenous glucocorticoid excess alter brain functioning on several time scales. Consequently, cognitive deficits and neuropsychological symptoms are highly prevalent during both active CS and CS in remission, as well as during glucocorticoid treatment. In this review, we discuss the effects of endogenous hypercortisolism and exogenously induced glucocorticoid excess on the brain, as well as the prevalence of cognitive and neuropsychological deficits and their course after biochemical remission. Furthermore, we propose possible mechanisms that may underly neuronal changes, based on experimental models and in vitro studies. Finally, we offer recommendations for future studies.


  • Open Access

    Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank

    by Merel van der Meulen, Jorge Miguel Amaya, Olaf M Dekkers, Onno C Meijer

    Objective: To test the hypothesis that systemic and inhaled glucocorticoid use is associated with changes in grey matter volume (GMV) and white matter microstructure. Design: Cross-sectional study. Setting: UK Biobank, a prospective population-based cohort study of adults recruited in the UK between 2006 and 2010. Participants: After exclusion based on neurological, psychiatric or endocrinological history, and use of psychotropic medication, 222 systemic glucocorticoid users, 557 inhaled glucocorticoid users and 24 106 controls with available T1 and diffusion MRI data were included. Main outcome measures: Primary outcomes were differences in 22 volumetric and 14 diffusion imaging parameters between glucocorticoid users and controls, determined using linear regression analyses adjusted for potential confounders. Secondary outcomes included cognitive functioning (six tests) and emotional symptoms (four questions). Results: Both systemic and inhaled glucocorticoid use were associated with reduced white matter integrity (lower fractional anisotropy (FA) and higher mean diffusivity (MD)) compared with controls, with larger effect sizes in systemic users (FA: adjusted mean difference (AMD)=−3.7e-3, 95% CI=−6.4e-3 to 1.0e-3; MD: AMD=7.2e-6, 95% CI=3.2e-6 to 1.1e-5) than inhaled users (FA: AMD=−2.3e-3, 95% CI=−4.0e-3 to −5.7e-4; MD: AMD=2.7e-6, 95% CI=1.7e-7 to 5.2e-6). Systemic use was also associated with larger caudate GMV (AMD=178.7 mm 3 , 95% CI=82.2 to 275.0), while inhaled users had smaller amygdala GMV (AMD=−23.9 mm 3 , 95% CI=−41.5 to −6.2) than controls. As for secondary outcomes, systemic users performed worse on the symbol digit substitution task (AMD=−0.17 SD, 95% CI=−0.34 to −0.01), and reported more depressive symptoms (OR=1.76, 95% CI=1.25 to 2.43), disinterest (OR=1.84, 95% CI=1.29 to 2.56), tenseness/restlessness (OR=1.78, 95% CI=1.29 to 2.41), and tiredness/lethargy (OR=1.90, 95% CI=1.45 to 2.50) compared with controls. Inhaled users only reported more tiredness/lethargy (OR=1.35, 95% CI=1.14 to 1.60). Conclusions: Both systemic and inhaled glucocorticoid use are associated with decreased white matter integrity and limited changes in GMV. This association may contribute to the neuropsychiatric side effects of glucocorticoid medication, especially with chronic use.


  • Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study

    by Merel van der Meulen, Marco J. T. Verstegen, Daniel J. Lobatto, Maarten C. Kleijwegt, Alberto M. Pereira, Nienke R. Biermasz, Wouter R. van Furth, Amir H. Zamanipoor Najafabadi

    Purpose Endoscopic transsphenoidal surgery causes nasal morbidity and negatively affects health-related quality of life (HRQoL). Knowledge on actionable symptoms that could improve postoperative HRQoL is therefore important. This study assessed the impact of nasal symptoms on postoperative HRQoL. Methods This perioperative cohort study included 103 adult patients undergoing endoscopic pituitary adenoma resection (August 2016–December 2018), with measurements preoperatively, and 5 days, 6 weeks and 6 months after surgery. Nasal symptoms were measured with the Anterior Skull base nasal inventory-12, and HRQoL with the Short Form-36 (SF-36) physical (PCS) and mental component scores (MCS). Linear regression analysis was used to assess (1) determinants of postoperative nasal morbidity, (2) associations between number of symptoms or (3) individual symptoms and HRQoL, and (4) the percentage of variance of HRQoL explained by nasal symptoms. Results The number of nasal symptoms transiently increased after surgery. No significant treatment- or disease-related determinants of nasal morbidity were identified. The number of nasal symptoms was significantly associated with a lower PCS (β = − 1.0; 95%CI − 1.5, − 0.4), but not with MCS at 6 weeks. Similar results were observed at 6 months. Headaches (42.2%), problems with smell (42.0%), and taste (36.0%) were the most prevalent symptoms, while sense of smell and taste, and nasal discharge showed the strongest associations with HRQoL. Conclusions Postoperative nasal symptoms, in particular problems with smell and taste, significantly affect pituitary patients’ physical HRQoL. Monitoring of these symptoms may aid in determining which patients may benefit from intensified follow-up and treatment, aiming to optimize HRQoL.


  • Open Access

    State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis

    by Merel van der Meulen, Amir H Zamanipoor Najafabadi, Leonie H A Broersen, Jan W Schoones, Alberto M Pereira, Wouter R van Furth, Kim M J A Claessen, Nienke R Biermasz

    Context: Insight into the current landscape of patient-reported outcome (PRO) measures (PROM) and differences between PROs and conventional biochemical outcomes is pivotal for future implementation of PROs in research and clinical practice. Therefore, in studies among patients with acromegaly and growth hormone deficiency (GHD), we evaluated (1) used PROMs, (2) their validity, (3) quality of PRO reporting, (4) agreement between PROs and biochemical outcomes, and (5) determinants of discrepancies. Evidence Acquisition: We searched 8 electronic databases for prospective studies describing both PROs and biochemical outcomes in acromegaly and GHD patients. Quality of PRO reporting was assessed using the International Society for Quality of Life Research (ISOQOL) criteria. Logistic regression analysis was used to evaluate determinants. Evidence Synthesis: Ninety studies were included (acromegaly: n = 53; GHD: n = 37). Besides nonvalidated symptom lists (used in 37% of studies), 36 formal PROMs were used [predominantly Acromegaly Quality of Life Questionnaire in acromegaly (43%) and Quality of Life-Assessment of Growth Hormone Deficiency in Adults in GHD (43%)]. Reporting of PROs was poor, with a median of 37% to 47% of ISOQOL items being reported per study. Eighteen (34%) acromegaly studies and 12 (32%) GHD studies reported discrepancies between PROs and biochemical outcomes, most often improvement in biochemical outcomes without change in PROs. Conclusions: Prospective studies among patients with acromegaly and GHD use a multitude of PROMs, often poorly reported. Since a substantial proportion of studies report discrepancies between PROs and biochemical outcomes, PROMs are pivotal in the evaluation of disease activity. Therefore, harmonization of PROs in clinical practice and research by development of core outcome sets is an important unmet need.


  • Open Access

    The Perspective of Pituitary Patients on Work According to the Expanded ICF Model: a Qualitative Study

    by Merel van der Meulen, Daniel J. Lobatto, Wouter R. van Furth, Sasja D. Huisman, Yvonne F. Heerkens, Thea P.M. Vliet Vlieland, Nienke R. Biermasz, Cornelie D. Andela

    Purpose: As the majority of patients with pituitary disease are of working age, their health situation may negatively impact their functioning at work. However, work participation can also be influenced by contextual (environmental and personal) factors. The aim of this qualitative study was to investigate the pituitary patients’ perspective on their functioning at work and on contextual factors contributing to work-related problems using the expanded International Classification of Functioning, Disability and Health (ICF).Methods: Semi-structured interviews, focusing on contextual factors influencing work ability and experience, were conducted with eight patients with different types of pituitary adenomas (Cushing’s disease, prolactinoma, acromegaly, non-functioning adenoma). Following the steps of an experiential thematic analysis, forty categories were identified, which were organized into eleven themes according to the expanded ICF. Results: Patients reported various problems in work-related activities and work participation. Influencing environmental factors included type of employment, perceived job security, financial security, relationships with colleagues/managers, collaboration with others, physical vs. mental work, managing position, flexibility at work, corporate culture, and physical work environment (work-related), and traveling distance to work, financial savings, and (non)professional support (other environmental factors). Influencing personal factors included professional ambition, sense of duty, motivation, job satisfaction, feeling of fulfilment (work-related), and personality, acceptance, coping styles, and lifestyle (general personal factors). Conclusion: Patients with pituitary disease report several contextual factors that influence their functioning at work. Healthcare and occupational health professionals should be aware of these factors to improve patients’ well-being and functioning at work, ultimately aiming to improve quality of life.